US2018092882A1PendingUtilityA1

Compositions and methods for the treatment of macular degeneration

59
Assignee: ALDEYRA THERAPEUTICS INCPriority: Dec 11, 2009Filed: Oct 12, 2017Published: Apr 5, 2018
Est. expiryDec 11, 2029(~3.4 yrs left)· nominal 20-yr term from priority
Inventors:Thomas A. JordanJohn C. ChabalaGerald D. Cagle
A61P 27/02A61P 27/06A61K 9/0048A61K 31/423A61K 31/47A61K 47/40
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic compound and an oligomeric or polymeric carrier.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A topical ophthalmic composition comprising a lipophilic compound selected from the group consisting of Compound A, Compound B and Compound C and a carrier selected from β-cyclodextrin sulfobutylether or a pharmaceutically acceptable salt thereof in an aqueous solution. 
     
     
         2 . The composition of  claim 1  wherein the lipophilic compound is Compound A or a pharmaceutically acceptable salt thereof. 
     
     
         3 . The composition of  claim 2  wherein the carrier is β-cyclodextrin sulfobutylether sodium salt. 
     
     
         4 . The composition of  claim 3  wherein the solution is an aqueous saline solution phosphate buffered to a pH of 6.5-7.5. 
     
     
         5 . The composition of  claim 4  wherein the concentration of β-cyclodextrin sulfobutylether sodium salt is 9.5-20% w/v. 
     
     
         6 . The composition of  claim 5  wherein the concentration of β-cyclodextrin sulfobutylether sodium salt is 9.5% w/v. 
     
     
         7 . A method for treating macular degeneration comprising administering a topical ophthalmic composition to the eye(s) of a patient, wherein said topical composition comprises a lipophilic compound selected from the group consisting of Compound A, Compound B and Compound C and a carrier selected from β-cyclodextrin sulfobutylether or a pharmaceutically acceptable salt thereof in an aqueous solution. 
     
     
         8 . The method of  claim 7  wherein the lipophilic compound is Compound A or a pharmaceutically acceptable salt thereof. 
     
     
         9 . The method of  claim 8  wherein the carrier is β-cyclodextrin sulfobutylether sodium salt. 
     
     
         10 . The method of  claim 9  wherein the solution is an aqueous saline solution phosphate buffered to a pH of 6.5-7.5. 
     
     
         11 . The method of  claim 10  wherein the concentration of β-cyclodextrin sulfobutylether sodium salt is 9.5-20% w/v. 
     
     
         12 . The method of  claim 11  wherein the concentration of β-cyclodextrin sulfobutylether is 9.5% w/v. 
     
     
         13 . The method of  claim 12  wherein the form of macular degeneration being treated is dry AMD. 
     
     
         14 . The method of  claim 12  wherein the form of macular degeneration being treated is geographic atrophy secondary to dry AMD. 
     
     
         15 . The method of  claim 12  wherein the form of macular degeneration being treated is wet AMD. 
     
     
         16 . The method of  claim 12  wherein the form of macular degeneration being treated is Stargardt's disease.

Join the waitlist — get patent alerts

Track US2018092882A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.